Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be
half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some …

Background Insulin icodec is an investigational once-weekly basal insulin analogue for
diabetes management. Methods We conducted a 78-week randomized, open-label, treat-to …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Background Insulin icodec (icodec) is a basal insulin analogue suitable for once-weekly
dosing. ONWARDS 4 aimed to assess the efficacy and safety of once-weekly icodec …

Background Insulin icodec (icodec) is a once-weekly basal insulin currently under
development. ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec …

At the time of its first clinical application 100 years ago, insulin was presented as the cure for
people with diabetes mellitus. That transpired to be an overstatement, yet insulin has proven …

Importance Once-weekly insulin icodec could provide a simpler dosing alternative to daily
basal insulin in people with type 2 diabetes. Objective To evaluate the efficacy and safety of …

Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …

Aim To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
basal insulin Fc (BIF; LY3209590), a fusion protein combining a novel single‐chain insulin …